• UCLA Health
  • myUCLAhealth
  • School of Medicine
UCLA Health

UCLA Health
  • About Us
    • What is UCLA Health?
    • Contact Us
    • Your Feedback
    • Accountable Care Organization
    • Awards & Achievements
    • Careers
    • Careers for Physicians
    • Departments - Administrative
    • Departments - Clinical
    • Giving to UCLA Health
    • In the Community
    • 340B Program
    • Industry Relations
    • Innovation
    • Leadership
    • News Releases
    • Price Transparency
    • Social Media
    Vital SignsLinked Graphic: Subscribe to Health Newsletters
    • Contact
    • Your Feedback
    • Accountable Care Organization
    • Awards and Achievements
    • Careers
    • Careers for Physicians
    • Departments - Administrative
    • Departments - Clinical
    • Giving to UCLA Health
    • Industry Relations
    • Innovation
    • In the Community
    • 340B Program
    • Leadership
    • News Releases
    • Price Transparency
    • Social Media
    • Subscribe to UCLA Health Newsletters
  • Conditions & Treatment
    • Health Library
    • Tests & Procedures
    • Drug Interaction Checker
    • Brain & Nervous System
    • Cancer
    • Children's Health
    • Heart Disease
    • Nutrition & Wellness
    • Pregnancy & Newborns
    • Orthopedics
    • Women's Health
    • Video Library
    • Cancer
    • Cardiovascular
    • Chiropractic
    • Cosmetic Surgery
    • Ear, Nose and Throat
    • Gastrointestinal
    • General Healthcare
    • Neurological
    • Obstetrics/Gynecology
    • See all videos...
    Symptom Checker
    • Video Library
  • Locations

    Hospitals

    • Ronald Reagan UCLA Medical Center
    • UCLA Medical Center, Santa Monica
    • UCLA Mattel Children's Hospital
    • Resnick Neuropsychiatric Hospital
    • Institutes and Centers
    • Take a Virtual Tour

    Medical Offices/Clinics

    • Primary Care
    • Specialty Care
    • Immediate Care
    • Emergency Care
    • Outpatient Surgery Centers
    • Community Cancer Care
    • Pediatric Locations
    • Imaging/Radiology
    • Clinical Labs
    • Pharmacies

    Interactive Map

    interactive map

    • Locations Coming Soon
    • UCLA Hospitals
    • Take a Virtual Tour
    • Primary Care Practices
    • Specialty Care Practices
    • Immediate Care
    • Emergency Care
    • Pediatric Locations
    • Outpatient Surgery Centers
    • Other Locations
    • Interactive Map
    • Coming Soon!
  • Medical Services
  • For Patients & Visitors
    • Directions & Parking
    • Appointments: Call, Click, Come In
    • Admissions
    • Preparing For Surgery
    • Patient Services
    • Security & Parking Services
    • Office of the Patient Experience
    • For International Patients
    • Lodging & Nearby Services
    • Around Westwood
    • Gift Shops & Flowers
    • Patient Greeting Cards
    • Log in to myUCLAhealth
    • Billing and Insurance
    • Medical Records
    • Accountable Care Organization (ACO)
    • Price Transparency
    • Interactive Patient Education Videos (Emmi)
    • FAQs
    • Calendar of Events
    • Secure Email Messages
    • Health Resources
    • Share your story. Connect. Share. Improve. UCLA Health
    • Share Your Story
    • Send a Care Compliment
    • Health Publications
    • Vital Signs Newsletters
    • Health Tips for Parents
    • Contact Us
    • Appointments: Call, Click, Come in
    • Admissions Information
    • Advance Directive
    • Directions & Parking
    • Patient Services
    • Medical Records
    • myUCLAhealth
    • Smoke-Free
    • Publications
    • Health Resources
    • Around Westwood
    • Lodging
    • Preparing For Surgery
    • Patient-focused Technology Council
    • Health Forms
    • End of Life Option Act: Resources & Materials
    • Frequently Asked Questions
    • Secure Email Messages
    • Gift Shops
  • For Healthcare Professionals
    • Referring a Patient
    • Continuing Medical Education
    • Ethics Center
    • UCLA HealthLink
    • Physician to Physician Access Line (P2P)
    • David Geffen School of Medicine at UCLA
    • Clinical Informatics Fellowship
    • Academic Positions
    • Physician Careers
    • UCLA School of Dentistry
    • UCLA School of Nursing
    • Department of Nursing

    Physician Publications

    • Physicians Update
    • Clinical Updates
    • U Magazine
    • Physician to Physician Access Line (P2P)
    • Physician Careers
    • Clinical Informatics Fellowship
    • Flu Resources for Healthcare Professionals
    • Publications
  • Multimedia
    • UCLAMDCHAT Webinars
    • Community Health Program Videos
    • Closer to a Cure LLS Series
    • iTunes
    • Download Our Apps
    • Mini Med School
    • Demystifying Cancer Forum
    • TEDx UCLA Videos
    • Tips from our Physical Therapists
    • Patient Stories
    • Real Questions
    • Webinars on Demand
    • Pediatric Grand Rounds
    • Tune in to watch our health webinars
    • Community Health Program Videos
    • UCLAMDChat Webinars
    • iTunes
    • Download Our Apps
    • UCLA Health Zone Radio and Podcast
    • Mini Med School
    • Closer to A Cure
    • Demystifying Cancer Forum
    • TEDx UCLA Videos
    • Tips From Our Physical Therapists
    • Patient Stories
    • Real Questions
    • Back Pain Management
  • Find a Provider
  • UCLA Health
  • myUCLAhealth
  • School of Medicine

News Releases

  1. Home
  2. About Us
  3. News Releases

News Releases

Health and Behavior

UCLA-led research reveals potential treatments for deadly tropical disease

One medicine is already FDA-approved for other uses, the second is a new synthetic antibiotic

09/11/2019
Philip Bulterys

Philip Bulterys and colleagues tested more than 220,000 compounds, thousands at a time.

Melioidosis is a tropical disease that claims an estimated 90,000 lives worldwide each year. There is no vaccine, and current treatments are hampered by the ability of the bacterium that causes the disease to resist even the strongest antibiotics.

Hardy and lethal, that bacterium, Burkholderia pseudomallei, is classified by the Centers for Disease Control and Prevention as a potential bioweapon.

UCLA-led research has identified two compounds that, based on tests on human cells and on mice, show potential for treating melioidosis. One is a widely used drug already approved by the U.S. Food and Drug Administration as an antifungal treatment; the other is a new synthetic antibiotic. The findings, published in the Proceedings of the National Academy of Sciences, represent progress against a disease about which little is known.

"Even among neglected tropical diseases, melioidosis is one of the most neglected, especially when you consider its global burden and lethality," said senior author Jeff F. Miller, UCLA's Fred Kavli Professor of NanoSystems Sciences, a professor of microbiology, immunology and molecular genetics, and director of the California NanoSystems Institute at UCLA. "It deserves more attention because of its fascinating biology as well."

Seen most often in southeast Asia and northern Australia, melioidosis can take many forms, ranging from a lethal bloodstream infection to a chronic infection that mimics other diseases like tuberculosis. B. pseudomallei can be contracted when contaminated soil or water is inhaled, swallowed or taken in through a wound or cut.

When it enters mammalian cells, the bacterium multiplies and can spread by causing infected cells to fuse with their neighbors. That capacity to fuse cells together is critical to the bacterium's lifecycle and its ability to cause disease. Eventually, complexes of fused cells burst, which can destroy the tissue in which the cells are located.

Working at the California NanoSystems Institute's robotic screening facility, and using a screening technique they developed, Miller and his colleagues tested a library of more than 220,000 compounds — thousands at a time — for their ability to interrupt the bacterial life cycle.

"The screen we developed would be easy to adapt to other intracellular pathogens, such as Mycobacterium, which causes tuberculosis," said Christopher Todd French, the paper's co-corresponding author and a UCLA assistant research professor. "It captures any compound that inhibits a step along the way from the bacterium getting into the cell, to it growing in the cell, to it spreading to nearby cells."

Because of the extensive safety precautions required to study B. pseudomallei, the researchers first screened the compounds on a less-dangerous relative, B. thailandensis, to narrow down the list of drugs that warranted further testing.

For each screening, human cells were robotically placed on lab plates, treated with the compounds to be tested, and then infected with the bacterium. After 20 hours, the scientists used an imaging method called laser scanning cytometry to take high-resolution images of the plates to identify the effects of each compound.

Compounds that disrupted B. thailandensis were then tested against B. pseudomallei and B. mallei, another closely related bacterium that causes glanders, a disease that's most commonly seen in horses and other animals but can also affect humans. Ultimately, the researchers identified 32 compounds that worked against B. pseudomallei, B. mallei or both.

The team focused on two compounds that were particularly effective against B. pseudomallei and showed minimal toxicity toward host cells. Both were able to enter the host cell and the bacterium — a significant development because getting compounds to cross both barriers is one of the key challenges in developing new antibiotics.

One of the two was flucytosine, or 5-FC, the antifungal medication already approved by the FDA. Researchers found that, rather than stopping the growth of B. pseudomallei, 5-FC worked by stopping the bacterium from fusing cells together and spreading.

That characteristic places 5-FC among an emerging class of antibiotics called antivirulence drugs, which could potentially be paired with traditional antibiotics — drugs that work by stopping bacteria from growing in the first place. That one-two punch could attack harmful bacteria more effectively while making antibiotic resistance less likely. Additionally, 5-FC is on the World Health Organization's Model List of Essential Medicines, meaning that it is available in resource-poor settings where melioidosis is endemic.

"A key priority will be to translate these laboratory findings into clinical impact," said Dr. Philip Bulterys, the study's first author and a recent graduate of the UCLA–Caltech Medical Scientist Training Program. "5-FC already has a well-established safety profile, which should make for a more rapid route to evaluating it as a new potential treatment for melioidosis."

The other potential new therapy, which the researchers dubbed burkfloxacin, or BFX, is a synthetic molecule related to antibiotics in the fluoroquinolone class, which includes the well-known drug ciprofloxacin. In the study, it was extremely effective at blocking B. pseudomallei's growth.

Studying mice infected with a lethal dose of B. pseudomallei, the scientists found that both 5-FC and BFX performed better than the current standard of care for melioidosis treatment, ceftazidime.

Other co-authors of the study include UCLA's Matteo Pellegrini, professor of molecular, cell and developmental biology, and Robert Damoiseaux, professor of molecular and medical pharmacology; and Michael Norris, Herbert Schweizer and Apichai Tuanyok, all of the University of Florida.

The research was supported by the National Institutes of Health, the Defense Threat Reduction Agency and the Paul and Daisy Soros Fellowship for New Americans.



Media Contact
Nikki Lin
310-206-8278
nlin@cnsi.ucla.edu



Latest News

Health and Behavior
ER visits did not rise with Medicaid expansion under Affordable Care Act
12/12/2019
Research brief: The findings also show that patient visits by Medicaid recipients to primary care physicians rose 3.6% during the first three years of the act.

Health and Behavior
Targeted therapy drug helps women with aggressive breast cancer live longer
12/11/2019
The drug combination should be a first line of treatment, UCLA researchers say.

Health and Behavior
Father's X chromosome may yield clues to higher rates of autoimmune disease in women
12/10/2019
UCLA researchers discovered differences in maternal and paternal X chromosomes that help explain sex differences in the immune system.

Health and Behavior
Researchers create accurate model of organ scarring using stem cells in a lab
12/10/2019
The advance could help scientists identify drugs to treat fibrosis, which plays a role in chronic kidney disease, liver cirrhosis and many other conditions.

Health and Behavior
UCLA study shows inhibition of gene helps overcome resistance to immunotherapy
12/09/2019
A combination approach could be new strategy for people with advanced cancers.

Facebook Twitter Instagram Youtube LinkedIn
UCLA Health hospitals ranked best hospitals by U.S. News & World Report
  • UCLA Health
  • Find a Doctor
  • School of Medicine
  • School of Nursing
  • UCLA Campus
  • Directory
  • Newsroom
  • Subscribe
  • Patient Stories
  • Giving
  • Careers
  • Volunteer
  • International Services
  • Privacy Practices
  • Nondiscrimination
  • Billing
  • Health Plans
  • Emergency
  • Report Broken Links
  • Terms of Use
  • 1-800-UCLA-MD1
  • Maps & Directions
  • Contact Us
  • Your Feedback
  • Report Misconduct
  • Get Social
  • Sitemap

Sign in to myUCLAhealth